Saurabh Saha - May 27, 2021 Form 3 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Executive Officer, Director
Signature
/s/ Marella Thorell, attorney-in-fact
Stock symbol
CNTA
Transactions as of
May 27, 2021
Transactions value $
$0
Form type
3
Date filed
5/27/2021, 08:32 PM
Next filing
Nov 18, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CNTA Share Option (right to buy) May 27, 2021 Ordinary Shares 4.17M $5.84 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
F2 Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.
F3 Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Remarks:

Exhibit 24 - Power of Attorney